Reducing tetracycline resistance in living cells
AssigneeTrustees of Tufts College
InventorStuart B. Levy
Life of this patent
Estimating the term…
Loading patent…
AssigneeTrustees of Tufts College
InventorStuart B. Levy
Estimating the term…
The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
A method for therapeutically treating a tetracycline resistant cell with tetracyclines, which comprises the steps of
A method for converting tetracycline resistant bacteria into tetracycline sensitive bacteria, comprising contacting the resistant bacteria with a predetermined quantity of at least a first composition selected from C5 esters of tetracycline, 13,5 derivative or 6-deoxy-13-(substituted mercapto)tetracyclines, and concomitantly administering to the cell a predetermined quantity of at least a second composition selected from a tetracycline, a tetracycline analogue or a tetracycline derivative which is not a C5 ester of tetracycline nor a 6-deoxy-13-(substituted mercapto)tetracycline.
A pharmaceutical preparation for converting tetracycline resistant bacteria into tetracycline sensitive bacteria comprising a blocking agent which is capable of interacting with a product of at least one tetracycline resistance determinant capable of protecting ribosomes in the cell from the inhibitory activity of tetracycline, a tetracycline type antibiotic, and a pharmaceutical carrier.
A pharmaceutical preparation for converting tetracycline resistant bacteria into tetracycline sensitive bacteria comprising a 6-deoxy-13(substituted mercapto)tetracycline, a tetracycline-type antibiotic which is not a 6-deoxy-13-(substituted mercapto)-tetracycline, and a pharmaceutically acceptable carrier.
A pharmaceutical preparation for converting tetracycline resistant bacteria into tetracycline sensitive bacteria comprising a C5 ester of tetracycline, a tetracycline-type antibiotic which is not a C5 ester of tetracycline, and a pharmaceutically acceptable carrier.
A pharmaceutical preparation for converting tetracycline resistant bacteria into tetracycline sensitive bacteria comprising a 13,5 derivative of tetracycline, a tetracycline-type antibiotic which is not a 13,5 derivative of tetracycline, and a pharmaceutically acceptable carrier.
A class of C5 esters of tetracycline compositions useful in combination with other classes of tetracyclines, tetracycline analogues and tetracycline derivatives, said class of compositions having the formula ##STR48## wherein R1 and R2 are selected from the group consisting of a methylene group, hydroxyl, hydrogen or a group consisting of organic entities comprising from 1-12 carbon atoms, with or without other heteroatoms including sulfur, oxygen, halogen, nitrogen, and the like, and takes form as linear, branched, or cyclic alkyl, aryl, or alkylaryl structures;
A class of 6-deoxy-13-(substituted mercapto) tetracyline compositions useful in the therapeutic treatment of a tetracycline resistant cell in combination with other classes of tetracyclines, tetracycline analogues and tetracycline derivatives, said class of compositions having the formula ##STR49## wherein A is hydrogen or hydroxyl, B comprises a morpholino group, and
Dependencies are inferred from the claim text.